Realizing the potential of long non-coding RNAs to develop transformative medicines

NextRNA is uniquely positioned to deliver transformative small molecule therapeutics targeting long non-coding RNAs (lncRNAs).

lncRNAs, a vast class of targets

Proprietary platform and unique capabilities

Small molecule development

NextRNA Therapeutics

DevelopING Transformative Medicines

Developing transformative medicines to address long non-coding RNA (lncRNA)-driven diseases

lncRNAs represent a vast class of therapeutic targets that recruit RNA-binding proteins (RBPs) to drive pathological processes across diseases. NextRNA’s unique therapeutic approach is to inhibit the function of lncRNAs by disrupting the interaction between lncRNAs and RBPs with small molecules.

Learn More

Proprietary platform and unique capabilities to
realize the therapeutic potential of lncRNAs

Our proprietary platform, unique capabilities, and deep lncRNA expertise position NextRNA to unlock the vast therapeutic opportunities presented by lncRNAs as a target class.

Learn More

01
NextRNA Therapeutics
We identify tissue-specific and disease-driving lncRNAs across therapeutic areas.
02
NextRNA Therapeutics
We validate the role of lncRNAs and characterize lncRNA-RBP interactions driving the mechanism of action in disease.
03
NextRNA Therapeutics
We develop functional small molecules to inhibit lncRNA function by disrupting lncRNA-RBP interactions.

Become a NextR

Our team is driven by a common passion to advance pioneering science that impacts patients.

Join Us

Top